Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Phase 3

Completed

• Conditions: Non-relapsing Secondary Progressive Multiple Sclerosis
• Interventions: Drug: Tolebrutinib; Drug: Placebo to match Tolebrutinib

• Registration Number: NCT04411641
• Lead Sponsor: Sanofi

Brief Summary

Primary Objective:

To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS

Secondary Objective:

To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168

Detailed Description

This was an event-driven (6-month CDP) trial with a variable treatment duration (end-of-study \[EOS\] duration: up to approximately 47months).

Participants with 6-month confirmed disability progression (CDP) had an option to receive tolebrutinib in the open-label (OL).

Study Timeline

• Study First Submitted: 2020-05-28
• Study First Submitted QC: 2020-05-28
• Study First Posted: 2020-06-02
• Study Start: 2020-09-24
• Primary Completion: 2024-08-29
• Study Completion: 2024-08-29
• Status Verified: 2025-06
• Results First Submitted: 2025-06-03
• Results First Submitted QC: 2025-06-03
• Results First Posted: 2025-06-18
• Last Update Submitted: 2025-07-01
• Last Update Posted: 2025-07-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1131

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SAR442168	Tolebrutinib	60 mg of oral SAR442168 once daily
Placebo	Placebo to match Tolebrutinib	Placebo tablet to match SAR442168 once daily

Primary Outcome Measures

Name	Time	Method
Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS)	Baseline (Day 1) up to approximately 47 months	The EDSS is a disability scale that assesses the following 7 functional domains: visual, brainstem, pyramidal \[motor\], cerebellar \[coordination\], sensory, cerebral, and bowel/bladder. The total EDSS ranges from 0 (normal) to 10 (death due to multiple sclerosis \[MS\]) (0.5 increments from 1-10; next increase after 0 is 1). Higher scores indicated increased disability. Time to onset of 6-month CDP was defined as the time from randomization to the onset of a sustained increase from baseline in EDSS score of \>=1.0 point from the baseline EDSS score when the baseline score was \<=5.0 or of \>=0.5 points when the baseline EDSS score was \>5.0 confirmed after a minimum 6-month interval.

Secondary Outcome Measures

Name	Time	Method
Time to Onset of 3-month Confirmed Disability Progression as Assessed by Expanded Disability Status Scale	Baseline (Day 1) up to approximately 47 months	The EDSS is a disability scale that assesses the following 7 functional domains: visual, brainstem, pyramidal \[motor\], cerebellar \[coordination\], sensory, cerebral, and bowel/bladder. The total EDSS ranges from 0 (normal) to 10 (death due to MS) (0.5 increments from 1-10; next increase after 0 is 1). Higher scores indicated increased disability. Time to onset of 3-month CDP was defined as the time from randomization to the onset of a sustained increase from baseline in EDSS score (of \>=1.0 point from the baseline EDSS score when the baseline score is \<=5.0, of \>=0.5 points when the baseline EDSS score is \>5.0) confirmed after a minimum 3-month interval. The confirmation of 3-month CDP followed the same criteria as that of 6-month CDP.
Mean Number of New and/or Enlarging T2-hyperintense Lesions Per Year	Baseline (Day 1) up to approximately 47 months	Magnetic resonance imaging (MRI) of the brain was performed to identify number of new and/or enlarging T2-hyperintense lesions defined as the sum of the individual number of new and/or enlarging T2 lesions from baseline up to and including the EOS visit.
Time to Onset of Sustained 20% Increase in the 9-hole Peg Test (HPT) for at Least 3 Months	Baseline (Day 1) up to approximately 47 months	The 9-HPT is a brief, standardized, quantitative test of upper extremity function and the time to complete the 9-HPT is used to assess a participant's manual dexterity and fine motor skills. A participant was asked to place the pegs into the holes and remove them with the dominant and non-dominant hand; two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs was recorded for each trial (ranging from 10 to 300 seconds). The mean time to test completion served for assessment of the participant's hand dexterity. Higher value indicated worse outcome. An increase of \>20% from the baseline in the 9-HPT was considered meaningful worsening; time to onset of sustained 20% increase for at least 3 months is presented.
Change From Baseline in Plasma Neurofilament Light Chain (NfL) and Serum Chitinase-3 Like Protein-1 (Chi3L1) Levels at EOS	Baseline (Day 1) to EOS (up to approximately 47 months)	Blood samples were collected at specified timepoints to assess change from baseline in NfL and Chi3L1. Baseline was defined as the last available value prior to the first dose of study intervention.
Time to Onset of Sustained 20% Increase in the Timed 25-foot Walk (T25-FW) for at Least 3 Months	Baseline (Day 1) up to approximately 47 months	The T25-FW test is a quantitative mobility and leg function performance test used to assess a participant's walking ability. A participant was directed to one end of a clearly marked 25-foot course and instructed to walk 25 feet as quickly as safely possible for 2 trials. The amount of time (in seconds) to walk 25 feet was recorded (ranging from 2.2 to 180 seconds). The mean walk time was used for assessment of the participant's walking ability. Higher value indicated worse outcome. An increase of \>20% from the baseline in the T25-FW test was considered meaningful worsening; time to onset of sustained 20% increase for at least 3 months is presented.
Time to Onset of 6-month Confirmed Disability Improvement (CDI) as Assessed by Expanded Disability Status Scale	Baseline (Day 1) up to approximately 47 months	The EDSS is a disability scale that assesses the following 7 functional domains: visual, brainstem, pyramidal \[motor\], cerebellar \[coordination\], sensory, cerebral, and bowel/bladder. The total EDSS ranges from 0 (normal) to 10 (death due to MS) (0.5 increments from 1-10; next increase after 0 is 1). Higher scores indicated increased disability. CDI was defined as a \>=1 point decrease in the EDSS score from baseline confirmed over at least 6 months.
Percent Change in Brain Volume at EOS Compared to Month 6	Month 6 to EOS (up to approximately 47 months)	MRI of the brain was performed to evaluate percent change in brain volume which is considered as a marker of the central nervous system degenerative process. Least squares (LS) mean is presented.
Change From Baseline in Cognitive Function as Assessed by Symbol Digit Modalities Test (SDMT) at EOS	Baseline (Day 1) to EOS (up to approximately 47 months)	The SDMT is used to assess processing speed, divided attention, visual scanning, tracking and motor speed. It involves a simple substitution task using a reference key. The number of correct substitutions and number of items completed within a 90 second interval (maximum 110 seconds) are recorded. A decrease of 4 points from baseline on the SDMT is considered meaningful worsening. The score was the number of correctly coded items from 0-110 in 90 seconds; higher scores indicated better outcome. LS mean is presented. Baseline was defined as the last available value prior to the first dose of study intervention.
Change From Baseline in Cognitive Function as Assessed by California Verbal Learning Test Second Edition (CVLT-II) at EOS	Baseline (Day 1) to EOS (up to approximately 47 months)	The CVLT-II is a verbal learning and memory test consisting of recall and recognition of a list of 16 words. The list was read by the examiner, participants listened to the list and reported as many of the items as possible. For each assessment, 5 trials were completed. Standardized scores were used for analysis. The maximum possible score was 80 and a minimum was 0. A higher score indicated better recall meaning improved cognitive function. LS mean is presented. Baseline was defined as the last available value prior to the first dose of study intervention.
Change From Baseline in Multiple Sclerosis Quality of Life-54 (MSQoL-54) Questionnaire Score at EOS	Baseline (Day 1) to EOS (up to approximately 47 months)	MSQoL-54 is standardized instrument with generic and MS-specific items which generates 12 subscales \& 2 single-item measures (satisfaction with sexual function \[1 item\] \& change in health \[1 item\].12 subscales are as follows:a:physical health (10 items),b:health perceptions (5 items), c:energy (5 items),d:role limitation physical (4 items),e:sexual function (4 items),f:pain (3 items),g:social function (3 items),h:health distress (4 items),i:overall quality of life (2 items),j:emotional well-being (5 items),k:role limitations emotional (3 items) and l:cognitive function (4 items).Physical health composite score was calculated as weighted sum of 'a to h' subscales and mental health composite score was calculated as weighted sum of 'i to l' subscales mentioned above.Each composite score was transformed linearly to common 0 (worst) to 100 (best) score range;LS mean is presented.Higher score indicated improved QoL.Baseline:last available value prior to first dose of study intervention.
Number of Participants With Treatment-emergent Adverse Events (AEs), Treatment-emergent Serious AEs, Treatment-emergent AEs Leading to Permanent Study Intervention Discontinuation, and Treatment-emergent Adverse Events of Special Interest (AESIs)	From first dose of study intervention (Day 1) up to end of follow-up, up to approximately 47 months	An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
Maximum Observed Plasma Concentration (Cmax) of Tolebrutinib and M2 Metabolite	30-90 minutes post-dose at Months 6, 9, and 12 and 2.5-5 hours post-dose at Months 6 and 12	Blood samples were collected at specified timepoints to assess Cmax of tolebrutinib and M2 metabolite using a population pharmacokinetics (PopPK) model.
Time to Maximum Observed Plasma Concentration (Tmax) of Tolebrutinib and M2 Metabolite	30-90 minutes post-dose at Months 6, 9, and 12 and 2.5-5 hours post-dose at Months 6 and 12	Blood samples were collected at specified timepoints to assess Tmax of tolebrutinib and M2 metabolite using a PopPK model.
Area Under the Plasma Concentration-time Curve Over the Last 24-hours Dosing Interval (AUC0-24) of Tolebrutinib and M2 Metabolite	30-90 minutes post-dose at Months 6, 9, and 12 and 2.5-5 hours post-dose at Months 6 and 12	Blood samples were collected at specified timepoints to assess AUC0-24 of tolebrutinib and M2 metabolite using a PopPK model.
Change From Baseline in Cluster of Differentiation (CD)19+ B Cells at EOS	Baseline (Day 1) to EOS (up to approximately 47 months)	Blood samples were collected at specified timepoints to assess change from baseline in CD19+ B cells. Baseline was defined as the last available value prior to the first dose of study intervention.
Change From Baseline in Serum Immunoglobulin (Ig) Levels at EOS	Baseline (Day 1) to EOS (up to approximately 47 months)	Blood samples were collected at specified timepoints to assess change from baseline in IgG and IgM levels. Baseline was defined as the last available value prior to the first dose of study intervention.

Trial Locations

Locations (306)

University of Alabama MS Center-Site Number:8400013; 🇺🇸 Birmingham, Alabama, United States

Center for Neurology and Spine-Site Number:8400089; 🇺🇸 Phoenix, Arizona, United States

Arcadia Neurology Center-Site Number:8400070; 🇺🇸 Arcadia, California, United States

UC San Diego ACTRI-Site Number:8400101; 🇺🇸 La Jolla, California, United States

Collaborative Neuroscience Research-Site Number:8400045; 🇺🇸 Long Beach, California, United States

Multiple Sclerosis Center-Site Number:8400143; 🇺🇸 Los Angeles, California, United States

University of San Francisco, Sandler Neurosciences Center-Site Number:8400137; 🇺🇸 San Francisco, California, United States

Harbor UCLA-Site Number:8400088; 🇺🇸 Torrance, California, United States

Regina Berkovich, MD, PhD-Site Number:8400059; 🇺🇸 West Hollywood, California, United States

Mountain Neurological Research Center, Inc.-Site Number:8400128; 🇺🇸 Basalt, Colorado, United States

Scroll for more (296 remaining)